AASLD 2018, San Francisco, “Final Results of a Phase 1b 28 Day Study of ABI-H0731, a Novel Core Inhibitor, in Non-Cirrhotic Viremic Subjects with Chronic HBV”

Nov 11, 2018

Supporting Materials